
COPY NUMBER CHANGES IN 1q21.3 AND 1q23.3 HAVE
DIFFERENT CLINICAL RELEVANCE IN OVARIAN TUMORS
Dimova I1, Orsetti B2, Theillet Ch.2, Dimitrov R.3, Toncheva DI1,* *Corresponding Author: Draga I. Toncheva, Department of Medical Genetics, Medical Faculty,
Medical University, 2 Zdrave str. SBALAG “Maichin dom,” 6 Fl., 1431, Sofia, Bulgaria; Tel./Fax:
+35-92-952-0357; E-mail: dragatoncheva@yahoo.com page: 29
|
MATERIALS AND METHODS
Ovarian Tumors for Tissue Microarray (TMA) Construction. A TMA containing 540 ovarian tumor samples from 540 patients was constructed. The average age of the patients in the cohort was 55.25 years. There were 278 malignant tumors, 39 low malignant potential tumors (LMP) and 223 benign tumors (Table 1). The histological variants were: 248 serous, 61 mucinous, 85 endometri-oid, two clear cell tumors, two Brenner tumors, 20 mixed epithelial tumors, 31 undifferentiated, 21 unclassified and 50 non epithelial tumors (granulosa-cell, germline-cell). The slides from all tumors were previously reviewed by a single pathologist. Tumor stage and grade were defined according to the International Federation of Gynecology and Obstetrics
(FIGO) and World Health Organization (WHO) criteria [11].
Investigated Bacterial Artificial Chromosome Clones from 1q and Genes They Contain. We investigated the BAC of 1q21.3-RP11-126K1, of 168,686 bp (http://genome.ucsc.edu/). This contains the following genes: PIP5K1A; RFX5; PIK4CB; SELENBP1, which encode for phospha-ditylinositol-4-phosphate-5-kinase a, RFX5 protein (involved in expression of MHC-II), phosphadityl-inositol-3-kinase, and Selen-binding protein 1, respectively.
We also investigated the BAC of 1q23.3-RP11-97G24, of 171,855 bp. It contains the genes SLAMF1; SLAMF6; CD84, which encode for signaling lymphocytic activation molecule family member 1 (involved in cytolysis activity of NK cells), signaling lymphocytic activation molecule family member 6, and protein of super family of immunoglobulin receptors, respectively.
Tissue Microarray. For TMA construction, a hematoxilin and eosin (H&E)-stained section was made from each block to define representative tumor areas. Tissue cylinders with a diameter of 0.6 mm were punched from tumor areas and brought into a recipient paraffin block using a custom-made precision instrument [12]. Samples were distributed in
one regular-sized recipient paraffin block containing 540 specimens. Five pm sections of the blocks were transferred to glass slides using a paraffin-sectioning aid system (adhesive coated slides, adhesive tape, UV-lamp; Instrumedics Inc., Hackensack, NJ, USA).
Fluorescence in situ Hybridization (FISH).
Prior to hybridization the slides were treated with xylene at 37°C, absolute ethanol at room tempara-ture and 1 M sodium thiocyanate at 80° C for depar-rafinization and pretreatment. Dual color FISH was performed using the locus RP11-126K1 (1q21.3) clone probe, conjugated with digoxigenin and detected in red, and locus RP11-97G24 (1q23.3) clone probe, conjugated with biotin and detected in green. Labeling of the probes was performed by nick-translation. Denaturation of the DNA was carried out at 75°C for 10 min. (probe mixture) or at 73°C for 5 min. (slides). The probe mixture was applied to the slides and hybridized overnight in a moist chamber at 37°C. The post hybridization washes were performed using formamide 50%/2xSSC. A three-step detection was achieved by blocking non specific signals with block buffer, first detection with FITC-avidin/ mouse anti-Dig, again blocking, second detection with anti-avidin/Dig anti-mouse IgG, blocking, and third detection with FITC-avidin/ anti-Dig rhodamine. The slides were counterstained with DAPI in antifade. The presence of more than five locus signals per cell or tight clusters in at least 10% of tumor cells was considered to connote amplification. The presence of 3-5 locus signals in at least 10% of tumor cells was considered to connote a gain.
Statistical Analysis. The relationship between copy number changes and clinicopathological data was estimated using the %2 test and the p value was calculated. A p value of <0.05 was required for significance.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|